Lazard Asset Management
LYEL icon

Lazard Asset Management’s Lyell Immunopharma LYEL Stock Holding History

Lazard Asset Management’s Portfolio LYEL Stock Details LYEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-9
Closed – – 2452
2024
Q4 		$0 Hold
9
– – ﹤0.01% 2429
2024
Q3 		$0 Sell
9
-17
-65% -$500 ﹤0.01% 2379
2024
Q2 		$0 Sell
26
-370
-93% -$17.6K ﹤0.01% 2353
2024
Q1 		$17K Sell
396
-224
-36% -$9.59K ﹤0.01% 1853
2023
Q4 		$23K Buy
620
+325
+110% +$11.7K ﹤0.01% 2042
2023
Q3 		$8K Buy
295
+11
+4% +$522 ﹤0.01% 2157
2023
Q2 		$17K Sell
284
-1,043
-79% -$57.7K ﹤0.01% 2126
2023
Q1 		$62K Buy
1,327
+914
+221% +$48.9K ﹤0.01% 1728
2022
Q4 		$28K Hold
413
– – ﹤0.01% 2056
2022
Q3 		$60K Buy
+413
New +$55.9K ﹤0.01% 1712

Other funds holding LYEL

MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
OPL
Orland Properties Ltd Road Town, Tortola, British Virgin Islands $267M AUM 5.05% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return